Skip to main content

Table 3 ADC patient characteristics and stratification by neuroendocrine marker

From: Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples

  ADC overall cohort ADC neuroendocrine marker positive ADC neuroendocrine marker negative p value
n % n % n %  
Patients 627 100 110 100 517 100  
Gender
 Male 365 58 67 61 298 58 0.528
 Female 262 42 43 39 219 42  
Age, median y (range) 63 (30–89) 63 (41–84) 63 (30–89) 0.373
TNM
 pT
  pT1 127 20 25 23 102 20 0.535
  pT2 388 62 63 57 325 63  
  pT3 94 15 17 15 77 15  
  pT4 18 3 5 5 13 3  
 pN
  pN0 314 50 63 57 251 49 0.068a
  pN1 94 15 14 13 80 15  
  pN2 192 31 28 25 164 32  
  pN3 5 1 0 0 5 1  
  pNX 22 4 5 5 17 3  
 pM
  pM1 26 4 2 2 24 5  
  pMX 601 96 108 98 493 95  
Stage
 I 254 41 46 42 208 40 0.153b
 II 130 21 29 26 101 20  
 III 217 35 33 30 184 36  
 IV 26 4 2 2 24 5  
Genetic aberrations
 KRAS 147c 36 29d 36 118e 36 0.732f
 EGFR 64c 16 10d 8 52 16  
 BRAF 14c 3 2d 3 12 4  
 ROS1 5c 1 1d 1 4 1  
 ALK 5c 1 0d 0 5 2  
  1. ADC adenocarcinoma, M metastases, N nodal stage, T tumor size, y year
  2. apN0 versus pN1/pN2/pN3; pNX not included
  3. bstage I versus II versus III/IV
  4. cavailable for 405 cases
  5. davailable for 80 cases
  6. eavailable for 327 cases
  7. fKRAS versus EGFR versus BRAF/ROS1/ALK